Growth Metrics

Innoviva (INVA) Operating Margin (2011 - 2026)

Innoviva posted quarterly Operating Margin of 38.94% for Q1 2026, down 781.0% year-on-year from 5.72% in Q1 2025, and up 103.06% on a QoQ basis from 1274.01% in Q4 2025.

Innoviva (INVA) has 16 years of Operating Margin data on file, last reported at 38.94% in Q1 2026.

  • For the quarter ending Q1 2026, Operating Margin fell 781.0% year-over-year to 38.94%; the trailing twelve-month figure through Mar 2026 stood at 35.05% (down 1107.0% YoY), and the FY2025 full-year result was 39.81%, down 671.0% from the prior year.
  • Operating Margin for Q1 2026 stood at 38.94%, up from 1274.01% in the prior quarter.
  • Across five years, Operating Margin topped out at 127.79% in Q3 2023 and bottomed at 1425.38% in Q1 2023.
  • The 5-year median for Operating Margin is 430.5% (2023), against an average of 459.37%.
  • The widest annual swing landed in 2022, when Operating Margin slumped 875506 bps; it then surged 110554 bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 982.68% in 2022, then soared by 56 bps to 430.5% in 2023, then sank by 98 bps to 853.36% in 2024, then plunged by 49 bps to 1274.01% in 2025, then jumped by 103 bps to 38.94% in 2026.
  • The last three Operating Margin figures came in at 38.94% (Q1 2026), 1274.01% (Q4 2025), and 32.08% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 38.10%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 17.83%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 23.02%
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn 38.94%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 38.94%
Dec 31, 2025 -1,274.01%
Sep 30, 2025 32.08%
Jun 30, 2025 48.61%
Mar 31, 2025 46.74%
Dec 31, 2024 -853.36%
Sep 30, 2024 48.31%
Jun 30, 2024 54.74%
Mar 31, 2024 -1,058.80%
Dec 31, 2023 -430.50%
Sep 30, 2023 127.79%
Jun 30, 2023 -982.55%
Mar 31, 2023 -1,425.38%
Dec 31, 2022 -982.68%
Sep 30, 2022 0.38%
Jun 30, 2022 -489.64%
Mar 31, 2022 -709.95%
Dec 31, 2021 -611.53%
Sep 30, 2021 96.62%
Jun 30, 2021 8,265.41%
Mar 31, 2021 -509.85%
Dec 31, 2020 -1,280.36%
Sep 30, 2020 95.19%
Jun 30, 2020 96.00%
Mar 31, 2020 96.74%
Dec 31, 2019 96.93%
Sep 30, 2019 92.45%
Jun 30, 2019 93.22%
Mar 31, 2019 94.54%
Dec 31, 2018 96.70%
Sep 30, 2018 93.48%
Jun 30, 2018 93.42%
Mar 31, 2018 77.69%
Dec 31, 2017 95.53%
Sep 30, 2017 82.28%
Jun 30, 2017 81.67%
Mar 31, 2017 72.47%
Dec 31, 2016 86.35%
Sep 30, 2016 83.82%
Jun 30, 2016 79.69%
Mar 31, 2016 72.52%
Dec 31, 2015 75.73%
Sep 30, 2015 62.19%
Jun 30, 2015 47.94%
Mar 31, 2015 10.80%
Dec 31, 2014 1.79%
Sep 30, 2014 -955.16%
Jun 30, 2014 -1,048.61%
Mar 31, 2014 -1,887.56%
Dec 31, 2013 -503.53%
Sep 30, 2013 -1,857.11%
Jun 30, 2013 -521.79%
Mar 31, 2013 -2,525.49%
Dec 31, 2012 33.88%
Sep 30, 2012 -2,332.17%
Jun 30, 2012 -6,827.72%
Mar 31, 2012 68.39%
Dec 31, 2011 -663.47%
Sep 30, 2011 -454.08%
Jun 30, 2011 -370.28%
Mar 31, 2011 -336.47%